FINHUB Insights

DXCM · Q1 FY26 · Mar 31, 2026

Dexcom Q1 FY26: where the revenue came from and where it went

Dexcom Q1 FY26: revenue $1.2B (+15% year over year). Net profit $0.2B. Largest cohort United States $0.8B. The whole income statement as a sankey diagram from the SEC filing.

Period
Mar 31, 2026
Reported
Apr 30, 2026 10-Q
Sankey diagram of Dexcom's income statement for Q1 FY26: revenue of $1.2 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$1.2B +15% year over year
Gross profit$0.8B 63% margin
Operating profit$0.3B 21% margin
Net profit$0.2B 17% margin

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 31, 2026).
ItemValueShare of revenueYear over year
Revenue 1.2 100% +15%
United States 0.8 67% +11%
International 0.4 33% +26%
Cost of revenue−0.433%
Gross profit0.863% margin+6pp
Research & development−0.112%−2pp
Sales & marketing−0.17%+0pp
SG&A−0.329%−1pp
Operating profit0.321% margin+9pp
Tax−0.1
Net profit0.217%+7pp
Filing on EDGAR More quarters of DXCM

Source of the numbers: tables in the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters